Results 51 to 60 of about 210,768 (294)

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus

open access: yesClinics, 2012
OBJECTIVE: To determine the serum levels of interferon alpha in childhood-onset systemic lupus erythematosus patients, their first-degree relatives and healthy controls and to evaluate the associations between serum interferon alpha and disease activity,
Mariana Postal   +5 more
doaj  

Tratamento clínico do linfangioma com alfa-2a-interferon Treatment of lymphangioma with interferon-alpha-2a

open access: yesJornal de Pediatria, 2001
OBJETIVO: descrever os resultados obtidos com o uso do alfa-2a-interferon no tratamento de pacientes pediátricos com linfangiomas irressecáveis ou refratários a outros tratamentos.
Reynaldo J.S.P. de Souza, Luiz G. Tone
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism [PDF]

open access: yes, 2003
Background. Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of chronic active hepatitis C. Polymorphisms in the promoter region of the TNF-alpha gene can alter the TNF-alpha expression and modify the host immune response.
Konig, A.   +8 more
core   +1 more source

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus

open access: yesClinics, 2012
OBJECTIVE: To determine the serum levels of interferon alpha in childhood-onset systemic lupus erythematosus patients, their first-degree relatives and healthy controls and to evaluate the associations between serum interferon alpha and disease activity,
Mariana Postal   +5 more
doaj  

Effect of interferon-alpha on experimental septal fibrosis of the liver - study with a new model

open access: yesMemorias do Instituto Oswaldo Cruz, 2001
Interferon-alpha is used in antiviral therapy in humans, mainly for viral hepatitis B and C. An anti-fibrotic effect of interferon has been postulated even in the absence of anti-viral response, which suggests that interferon directly inhibits ...
Marcia Maria de Souza   +5 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

Evaluation of the effectiveness and safety of interferon alpha-2b ointment and gel for prevention of acute respiratory infections in organized groups

open access: yesЖурнал инфектологии
Relevance: the annual incidence of acute respiratory infections (ARI) is in the lead in the structure of infectious pathology in the Russian Federation.
K. V. Kozlov   +9 more
doaj   +1 more source

Interferon alpha (IFN-α) in systemic lupus erythematosus (SLE)

open access: yesJournal of Education, Health and Sport, 2022
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology. An important role in the pathogenesis of SLE has been attributed to interferon alpha (IFN-α), which stimulates the expression of numerous genes, resulting in an increased ...
Sara Moqbil   +4 more
doaj   +1 more source

Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling

open access: yesFEBS Open Bio, EarlyView.
Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy